COVID-19与造血干细胞移植:EBMT与GETH多中心前瞻性调查结果
该研究基于EBMT和GETH登记的多中心前瞻性调查,纳入382例接受异基因(236例)或自体(146例)造血干细胞移植后感染COVID-19的患者。中位年龄异基因54.1岁、自体60.6岁。83.5%发生下呼吸道疾病,22.5%入住ICU;诊断后6周总生存率异基因77.9%、自体72.1%,儿童93.4%。多因素分析显示高龄、需ICU及中/高免疫缺陷指数增加死亡风险,较好体能状态降低风险。
要点
- 移植后COVID-19患者下呼吸道疾病发生率达83.5%,ICU入住率22.5%。
- 诊断后6周总生存率异基因77.9%、自体72.1%,儿童达93.4%。
- 高龄、需ICU和中/高免疫缺陷指数是死亡危险因素,较好体能状态为保护因素。
核心结论
- 造血干细胞移植患者感染COVID-19后发生下呼吸道疾病和入住ICU的风险高,死亡率增加。
研究设计与样本
- 多中心前瞻性调查,纳入EBMT或GETH登记的382例移植后COVID-19患者,其中异基因236例、自体146例。
主要发现
- 83.5%的患者发生下呼吸道疾病,22.5%入住ICU。
- 诊断后6周总生存率异基因移植受者为77.9%,自体移植受者为72.1%,儿童为93.4%。
- 多因素分析中,高龄(p=0.02)、需ICU(p<0.0001)和中/高免疫缺陷指数(p=0.04)增加死亡风险,较好体能状态(p=0.001)降低风险。
- 基础诊断、移植至COVID-19时间、GVHD或持续免疫抑制对总生存无显著影响。
临床怎么用
- 移植后患者感染COVID-19应警惕下呼吸道疾病和ICU入住风险,需密切监测病情变化。
- 对高龄、体能状态较差或免疫缺陷指数较高的移植后COVID-19患者应加强风险管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study reports on 382 COVID-19 patients having undergone allogeneic (n = 236) or autologous (n = 146) hematopoietic cell transplantation (HCT) reported to the European Society for Blood and Marrow Transplantation (EBMT) or to the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH). The median age was 54.1 years (1.0-80.3) for allogeneic, and 60.6 years (7.7-81.6) for autologous HCT patients. The median time from HCT to COVID-19 was 15.8 months (0.2-292.7) in allogeneic and 24.6 months (-0.9 to 350.3) in autologous recipients. 83.5% developed lower respiratory tract disease and 22.5% were admitted to an ICU. Overall survival at 6 weeks from diagnosis was 77.9% and 72.1% in allogeneic and autologous recipients, respectively. Children had a survival of 93.4%. In multivariate analysis, older age (p = 0.02), need for ICU (p < 0.0001) and moderate/high immunodeficiency index (p = 0.04) increased the risk while better performance status (p = 0.001) decreased the risk for mortality. Other factors such as underlying diagnosis, time from HCT, GVHD, or ongoing immunosuppression did not significantly impact overall survival. We conclude that HCT patients are at high risk of developing LRTD, require admission to ICU, and have increased mortality in COVID-19.
引用
- Ljungman P, de la Camara R, Mikulska M, et al. COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. Leukemia. 2021. PMID: 34079042. doi:10.1038/s41375-021-01302-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。